Robert Bourge
Cardiovascular Disease · Birmingham, ALNPI 1598712424
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,969 of the $26,436 with a category attached, or 94.4%. 5 manufacturers reported payments, led by Abbott at 56.6% of the total. Reporting peaked in 2019 at $10,212 and has fallen 98.0% since, to $200 in 2023. Among cardiovascular disease clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $1468.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$15K
- United Therapeutics Corporation$5K
- Orphai Therapeutics Inc.$5K
- W. L. Gore & Associates, Inc.$1K
- Bayer$200
Across 113 payments — averaging $6380.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$470K
- Medtronic$251K
What the payments were for
- Consulting fees$24,96994%
- Speaking & faculty fees$1,0004%
- Travel & lodging$3211%
- Food & beverage$1461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 10 | $14,969 |
| United Therapeutics Corporation | 5 | $5,267 |
| Orphai Therapeutics Inc. | 1 | $5,000 |
| W. L. Gore & Associates, Inc. | 1 | $1,000 |
| Bayer | 1 | $200 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$14,969
- NONE$5,222
- Product in Development$1,000
- Adempas$200
How this compares
$26,436 in reported general payments places this provider in the 90th percentile of 292 cardiovascular disease providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 11 | $151 |
| Carvedilol | 11 | $89 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Birmingham
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Thomas CawthonBirmingham$54K
- Weihan ChenBirmingham$51K
- Farrell MendelsohnBirmingham$51K
- Charles MooreBirmingham$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.